Department of Medical Physiology, Texas A&M University College of Medicine, Bryan, TX.
Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN.
Hepatology. 2021 Jun;73(6):2411-2428. doi: 10.1002/hep.31545. Epub 2021 May 22.
Apelin (APLN) is the endogenous ligand of its G protein-coupled receptor, apelin receptor (APJ). APLN serum levels are increased in human liver diseases. We evaluated whether the APLN-APJ axis regulates ductular reaction and liver fibrosis during cholestasis.
We measured the expression of APLN and APJ and serum APLN levels in human primary sclerosing cholangitis (PSC) samples. Following bile duct ligation (BDL) or sham surgery, male wild-type (WT) mice were treated with ML221 (APJ antagonist) or saline for 1 week. WT and APLN mice underwent BDL or sham surgery for 1 week. Multidrug resistance gene 2 knockout (Mdr2 ) mice were treated with ML221 for 1 week. APLN levels were measured in serum and cholangiocyte supernatants, and cholangiocyte proliferation/senescence and liver inflammation, fibrosis, and angiogenesis were measured in liver tissues. The regulatory mechanisms of APLN-APJ in (1) biliary damage and liver fibrosis were examined in human intrahepatic biliary epithelial cells (HIBEpiCs) treated with APLN and (2) hepatic stellate cell (HSC) activation in APLN-treated human HSC lines (HHSteCs). APLN serum levels and biliary expression of APLN and APJ increased in PSC samples. APLN levels were higher in serum and cholangiocyte supernatants from BDL and Mdr2 mice. ML221 treatment or APLN reduced BDL-induced and Mdr2 -induced cholangiocyte proliferation/senescence, liver inflammation, fibrosis, and angiogenesis. In vitro, APLN induced HIBEpiC proliferation, increased nicotinamide adenine dinucleotide phosphate oxidase 4 (Nox4) expression, reactive oxygen species (ROS) generation, and extracellular signal-regulated kinase (ERK) phosphorylation. Pretreatment of HIBEpiCs with ML221, diphenyleneiodonium chloride (Nox4 inhibitor), N-acetyl-cysteine (NAC, ROS inhibitor), or PD98059 (ERK inhibitor) reduced APLN-induced cholangiocyte proliferation. Activation of HHSteCs was induced by APLN but reduced by NAC.
The APLN-APJ axis induces cholangiocyte proliferation through Nox4/ROS/ERK-dependent signaling and HSC activation through intracellular ROS. Modulation of the APLN-APJ axis may be important for managing cholangiopathies.
Apelin(APLN)是其 G 蛋白偶联受体 Apelin 受体(APJ)的内源性配体。APLN 血清水平在人类肝脏疾病中升高。我们评估了 APLN-APJ 轴在胆汁淤积时是否调节胆管反应和肝纤维化。
我们测量了人原发性硬化性胆管炎(PSC)样本中 APLN 和 APJ 的表达和血清 APLN 水平。在胆管结扎(BDL)或假手术后,雄性野生型(WT)小鼠用 ML221(APJ 拮抗剂)或生理盐水处理 1 周。WT 和 APLN 小鼠接受 BDL 或假手术 1 周。多药耐药基因 2 敲除(Mdr2)小鼠用 ML221 处理 1 周。测量血清和胆管细胞上清液中的 APLN 水平,并测量肝组织中的胆管细胞增殖/衰老、肝脏炎症、纤维化和血管生成。在接受 APLN 处理的人肝内胆管上皮细胞(HIBEpiC)中,研究了 APLN-APJ 在(1)胆汁损伤和肝纤维化中的调节机制,以及在 APLN 处理的人 HSC 系(HHSteC)中 HSC 激活的调节机制。在接受 APLN 处理的人 HSC 系(HHSteC)中,研究了 APLN-APJ 在(1)胆汁损伤和肝纤维化中的调节机制。在接受 APLN 处理的人 HSC 系(HHSteC)中,研究了 APLN-APJ 在(1)胆汁损伤和肝纤维化中的调节机制。APLN 血清水平和胆管细胞中 APLN 和 APJ 的表达在 PSC 样本中增加。BDL 和 Mdr2 小鼠的血清和胆管细胞上清液中的 APLN 水平更高。ML221 治疗或 APLN 减少了 BDL 诱导和 Mdr2 诱导的胆管细胞增殖/衰老、肝脏炎症、纤维化和血管生成。在体外,APLN 诱导 HIBEpiC 增殖,增加烟酰胺腺嘌呤二核苷酸磷酸氧化酶 4(Nox4)表达、活性氧(ROS)生成和细胞外信号调节激酶(ERK)磷酸化。用 ML221、二苯基碘(Nox4 抑制剂)、N-乙酰半胱氨酸(NAC,ROS 抑制剂)或 PD98059(ERK 抑制剂)预处理 HIBEpiC 可减少 APLN 诱导的胆管细胞增殖。APLN 诱导 HHSteC 激活,但 NAC 可减少其激活。
APLN-APJ 轴通过 Nox4/ROS/ERK 依赖性信号诱导胆管细胞增殖,并通过细胞内 ROS 诱导 HSC 激活。调节 APLN-APJ 轴可能对管理胆管病很重要。